---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056297"
form_type: "8-K"
ticker: null
cik: "0001673772"
company_name: "RAPT Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:21:09.419167+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# RAPT closes Phase 2b/2a trials after FDA hold due to liver failure SAE; Q1 net loss $30.5M

## Summary
- Company to close and unblind Phase 2b atopic dermatitis and Phase 2a asthma trials of zelnecirnon following FDA clinical hold.
- Clinical hold triggered by one patient liver failure requiring transplant; 229 patients enrolled in AD trial.
- Net loss of $30.5M for Q1 2024 vs $29.3M in Q1 2023; cash and equivalents $141.6M.
- Data analysis from AD trial expected Q3 2024 to inform development path and FDA discussions.

## SEC filing metadata
- accession: 0000950170-24-056297
- form_type: 8-K
- cik: 0001673772
- company_name: RAPT Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1673772/000095017024056297/0000950170-24-056297-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1673772/000095017024056297/rapt-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056297
- JSON: https://secwatch.observer/filing/0000950170-24-056297.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056297.txt

## Key facts
- Earnings Releases
  RAPT Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $30.5 million.
  - Period: the quarter ended March 31, 2024
  - Net income: Net loss for the first quarter of 2024 was $30.5 million
  - Result: reported results
  source text: RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1673772/000095017024056297/0000950170-24-056297-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.